FIA
TELO icon

FNY Investment Advisers’s Telomir Pharmaceuticals TELO Stock Holding History

FNY Investment Advisers’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,900
Closed -$77 – 855
2024
Q1 		$77 Buy
+14,900
New +$113K 0.05% 215

Other funds holding TELO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BHWM
Beaird Harris Wealth Management Dallas, Texas $1.6B AUM 16.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

FNY Investment Advisers's TELO Position: Q2 2024 in Review

FNY Investment Advisers sold out of Telomir Pharmaceuticals (TELO) in Q2 2024, closing a stake of 14,900 shares — an estimated $77 sold.

FNY Investment Advisers first reported a position in TELO in Q1 2024 and held it in 1 quarter. The position peaked at $77 in Q1 2024. 25 funds tracked by Wall St. Rank hold TELO as of Q2 2024.

  • FNY Investment Advisers reported no remaining Telomir Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 14,900 Telomir Pharmaceuticals shares in Q2 2024, an estimated $77.
  • FNY Investment Advisers first reported a position in Telomir Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • FNY Investment Advisers's Telomir Pharmaceuticals position peaked at $77 in Q1 2024.
  • 25 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2024.

Based on FNY Investment Advisers's 13F filing for Q2 2024, filed 5 Aug 2024.